Amyloid-β PET and CSF in an autopsy-confirmed cohort.
Juhan ReimandBaayla Dimitri Catharina BoonLyduine E CollijCharlotte E TeunissenAnnemieke J M RozemullerBart N M van BerckelPhilip ScheltensRik OssenkoppeleFemke H BouwmanPublished in: Annals of clinical and translational neurology (2020)
Our study demonstrates neuropathological underpinnings of amyloid-β CSF/PET discordance. Furthermore, amyloid-β biomarker positivity on both PET and CSF did not invariably result in an AD diagnosis at autopsy, illustrating the importance of considering relevant comorbidities when evaluating amyloid-β biomarker results.